BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18309249)

  • 1. [Distribution of antigenic aberration in the bone marrow of acute leukemia in complete remission].
    Shin S; Kahng J; Kim M; Lim J; Kim Y; Han K
    Korean J Lab Med; 2008 Feb; 28(1):1-7. PubMed ID: 18309249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
    Kahng J; Shin SY; Han K
    Korean J Lab Med; 2007 Dec; 27(6):406-13. PubMed ID: 18160830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows.
    Venditti A; Del Poeta G; Stasi R; De Fabriitis P; Coppetelli U; Bruno A; Simone MD; Papa G
    Haematologica; 1993; 78(6):359-63. PubMed ID: 7513673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
    Cáp J; Babusíková O; Kaiserová E; Jamárik M
    Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of minimal residual disease in acute myeloid leukemia.
    Gerhartz HH; Schmetzer H
    Leukemia; 1990 Jul; 4(7):508-16. PubMed ID: 1695705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease.
    Macedo A; Orfao A; Ciudad J; Gonzalez M; Vidriales B; Lopez-Berges MC; Martínez A; Landolfi C; Cañizo C; San Miguel JF
    Leukemia; 1995 Nov; 9(11):1896-901. PubMed ID: 7475281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
    Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
    Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens.
    Syrjälä M; Anttila VJ; Ruutu T; Jansson SE
    Leukemia; 1994 Sep; 8(9):1564-70. PubMed ID: 7522295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
    Wongprajun S; Auewarakul CU
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between CD19 and CD20 expression patterns on acute leukemic cells.
    Ning BT; Tang YM; Chen YH; Shen HQ; Qian BQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):943-7. PubMed ID: 16403255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
    Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
    Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia.
    Coustan-Smith E; Behm FG; Hurwitz CA; Rivera GK; Campana D
    Leukemia; 1993 Jun; 7(6):853-8. PubMed ID: 7684798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.